96: Quantification of cell free fetal DNA in maternal circulation as a marker of adverse pregnancy outcomes

2015 ◽  
Vol 212 (1) ◽  
pp. S65-S66
Author(s):  
Edward Wolf ◽  
Victoria DeSantos ◽  
Christopher McNamara ◽  
Natalie Porat ◽  
Richard Miller ◽  
...  
Keyword(s):  
Pregnancy Outcomes ◽  
Adverse Pregnancy Outcomes ◽  
Maternal Circulation ◽  
Fetal Dna ◽  
Cell Free Fetal Dna ◽  
Adverse Pregnancy

scholarly journals Cell-free fetal DNA and spontaneous preterm birth

Reproduction ◽  
2018 ◽  
Vol 155 (3) ◽  
pp. R137-R145 ◽  
Author(s):  
Sara R van Boeckel ◽  
Donald J Davidson ◽  
Jane E Norman ◽  
Sarah J Stock
Keyword(s):  
Preterm Birth ◽  
Clinical Studies ◽  
Spontaneous Preterm Birth ◽  
Maternal Circulation ◽  
Fetal Dna ◽  
Cell Free Fetal Dna ◽  
Adult Cell ◽  
Adverse Pregnancy ◽  
Sting Pathway ◽  
Preclinical And Clinical Studies

Inflammation is known to play a key role in preterm and term parturition. Cell-free fetal DNA (cff-DNA) is present in the maternal circulation and increases with gestational age and some pregnancy complications (e.g. preterm birth, preeclampsia). Microbial DNA and adult cell-free DNA can be pro-inflammatory through DNA-sensing mechanisms such as Toll-like receptor 9 and the Stimulator of Interferon Genes (STING) pathway. However, the pro-inflammatory properties of cff-DNA, and the possible effects of this on pregnancy and parturition are unknown. Clinical studies have quantified cff-DNA levels in the maternal circulation in women who deliver preterm and women who deliver at term and show an association between preterm labor and higher cff-DNA levels in the 2nd, 3rd trimester and at onset of preterm birth symptoms. Together with potential pro-inflammatory properties of cff-DNA, this rise suggests a potential mechanistic role in the pathogenesis of spontaneous preterm birth. In this review, we discuss the evidence linking cff-DNA to adverse pregnancy outcomes, including preterm birth, obtained from preclinical and clinical studies.

scholarly journals 323: A comparison between PAPP-A and free fetal DNA in maternal serum to predict adverse pregnancy outcomes

2016 ◽  
Vol 214 (1) ◽  
pp. S183
Author(s):  
Natalie Porat ◽  
Edward Wolf ◽  
Megan Dimoff ◽  
Melanie Lagomichos ◽  
Neha Rana
Keyword(s):  
Pregnancy Outcomes ◽  
Maternal Serum ◽  
Adverse Pregnancy Outcomes ◽  
Fetal Dna ◽  
Adverse Pregnancy

scholarly journals The Role of miRNAs as Biomarkers for Pregnancy Outcomes: A Comprehensive Review

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Martina Barchitta ◽  
Andrea Maugeri ◽  
Annalisa Quattrocchi ◽  
Ottavia Agrifoglio ◽  
Antonella Agodi
Keyword(s):  
Environmental Exposure ◽  
Pregnancy Outcomes ◽  
Methodological Approach ◽  
Placental Tissue ◽  
Adverse Pregnancy Outcomes ◽  
Maternal Circulation ◽  
Altered Expression ◽  
Comprehensive Review ◽  
Adverse Pregnancy

Several studies showed that altered expression of the miRNA-ome in maternal circulation or in placental tissue may reflect not only gestational disorders, such as preeclampsia, spontaneous abortion, preterm birth, low birth weight, or macrosomia, but also prenatal exposure to environmental pollutants. Generally, the relationships between environmental exposure, changes in miRNA expression, and gestational disorders are explored separately, producing conflicting findings. However, validation of tissue-accessible biomarkers for the monitoring of adverse pregnancy outcomes needs a systematic methodological approach that takes also into account early-life environmental exposure. To achieve this goal, exposure to xenochemicals, endogenous agents, and diet should be assessed. This study has the aim to provide a comprehensive review on the role of miRNAs as potential biomarkers for adverse pregnancy outcomes and prenatal environmental exposure.

Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-analysis

2020 ◽  
Vol 26 ◽  
Author(s):  
Yang Zhang ◽  
Dandan Li ◽  
Heng Guo ◽  
Weina Wang ◽  
Xingang Li ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Preterm Birth ◽  
Spontaneous Abortion ◽  
Bowel Disease ◽  
Pregnancy Outcomes ◽  
Congenital Malformations ◽  
Meta Analysis ◽  
Adverse Pregnancy Outcomes ◽  
Inflammatory Bowel ◽  
Adverse Pregnancy

Background: Conflicting data exist regarding the influence of thiopurines exposure on adverse pregnancy outcomes in female patients with inflammatory bowel disease (IBD). Objective: The aim of this study was to provide an up-to-date and comprehensive assessment of the safety of thiopurines in pregnant IBD women. Methods: All relevant articles reporting pregnancy outcomes in women with IBD received thiopurines during pregnancy were identified from the databases (PubMed, Embase, Cochrane Library, and ClinicalTrials.gov) with the publication data up to April 2020. Data of included studies were extracted to calculate the relative risk (RR) of multiple pregnancy outcomes: congenital malformations, low birth weight (LBW), preterm birth, small for gestational age (SGA), and spontaneous abortion. The meta-analysis was performed using the random-effects model. Results: Eight studies matched with the inclusion criteria and a total of 1201 pregnant IBD women who used thiopurines and 4189 controls comprised of women with IBD received drugs other than thiopurines during pregnancy were included. Statistical analysis results demonstrated that the risk of preterm birth was significantly increased in the thiopurine-exposed group when compared to IBD controls (RR, 1.34; 95% CI, 1.00-1.79; p=0.049; I 2 =41%), while no statistically significant difference was observed in the incidence of other adverse pregnancy outcomes. Conclusion: Thiopurines’ use in women with IBD during pregnancy is not associated with congenital malformations, LBW, SGA, or spontaneous abortion, but appears to have an association with an increased risk of preterm birth.

The Need for Personalized Risk-Stratified Approaches to Treatment for Gestational Diabetes: A Narrative Review

2021 ◽  
Author(s):  
Shamil D. Cooray ◽  
Jacqueline A. Boyle ◽  
Georgia Soldatos ◽  
Shakila Thangaratinam ◽  
Helena J. Teede
Keyword(s):  
Gestational Diabetes ◽  
Pregnancy Outcomes ◽  
Population Based ◽  
Adverse Pregnancy Outcomes ◽  
Therapeutic Interventions ◽  
Clinical Prediction Model ◽  
Increased Risk ◽  
Adverse Pregnancy ◽  
The Individual ◽  
Personalized Risk

AbstractGestational diabetes mellitus (GDM) is common and is associated with an increased risk of adverse pregnancy outcomes. However, the prevailing one-size-fits-all approach that treats all women with GDM as having equivalent risk needs revision, given the clinical heterogeneity of GDM, the limitations of a population-based approach to risk, and the need to move beyond a glucocentric focus to address other intersecting risk factors. To address these challenges, we propose using a clinical prediction model for adverse pregnancy outcomes to guide risk-stratified approaches to treatment tailored to the individual needs of women with GDM. This will allow preventative and therapeutic interventions to be delivered to those who will maximally benefit, sparing expense, and harm for those at a lower risk.

Sign in / Sign up

Export Citation Format

Share Document